ClinicalTrials.gg
CompletedNCT05847322Updated Oct 6, 2026

Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks

An interventional study of Bordetella pertussis B1917 and Azithromycin Pill in Healthy Volunteer Study, sponsored by University of Southampton. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of Southampton · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2022, registered Mar 2023).
Updated Oct 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Primary objective- To assess the safety of nasal inoculation of healthy volunteers with B. pertussis with antibiotic therapy given to eradicate colonisation at 6 weeks after inoculation or at symptom onset, whichever occurs first

Secondary objectives - To measure the rate of natural clearance of carriage of B. pertussis following nasal inoculation

  • To assess the kinetics of B. pertussis colonisation density following nasal inoculation
  • To describe the microevolution of B. pertussis and adaptation of the resident microbiome during B. pertussis carriage
  • To measure B. pertussis-specific antibody and cellular immunological responses in healthy volunteers during colonisation with B. pertussis - To identify biomarkers that correlate with natural clearance of B. pertussis carriage after induced B. pertussis colonisation
  • To detect transmission of B. pertussis to bedroom contacts of inoculated volunteers during prolonged asymptomatic colonisation
Read the detailed description

This is a prospective controlled human challenge study; Challenge group: The challenge volunteers will be healthy volunteers, aged 18-55 years, not having close contact with people having increased risk of severe pertussis complications or increased risk of transmitting to vulnerable individuals. Eligible volunteers must be willing to abide by infection control measures during social contact and to attend immediately if they become symptomatic. People who live in institutions in which multiple people share dormitory facilities, such as boarding schools or military barracks will be excluded.

The standard inoculum, a dose of 105 cfu, determined in Phase A of the Bp human challenge study, will be used. Participants will be followed up weekly and colonisation will be measured in nasal washes. If culture of the nasal wash taken at week 5 following nasal inoculation is positive for B. pertussis, then eradication therapy will be given at week 6. Early eradication therapy will be given if a participant presents with symptoms of early B. pertussis disease.

Recruitment will continue until 10 challenge volunteers have been colonised and then completed study participation to week 6 as per protocol. Volunteers who withdraw from the study early or have colonisation cleared with antibiotic treatment given for any reason will be replaced. Assuming a colonisation fraction of at least 30% and allowing for study withdrawal the investigator expect a maximum number of 36 volunteers to be inoculated.

Contact group: A group of contact volunteers, maximum 36 individuals, will be enrolled to assess transmission by monitoring for colonisation with the challenge strain of B. pertussis. These contact volunteers will be bedroom sharers of challenge volunteers and will give informed consent for their participation in the study, prior to inoculation of the corresponding challenge volunteer. Eradication therapy will be given at week 6 if the culture of nasal wash is positive for B. pertussis at week 5. Early eradication therapy will be given if a contact volunteer presents with symptoms of early B. pertussis disease.

Challenge and contact volunteers will be required to agree to infection control measures prior to enrolment in the study. Part of this agreement will be to refrain from bedroom sharing or intimate contact with any individual other than one declared and consented bedroom contact. They will avoid contact with children or people vulnerable to whooping cough such as unimmunised or partially immunised children and infants aged \< 1 year, and pregnant women.

02

Conditions studied

  • Healthy Volunteer Study
03

In context

Lead sponsor

University of Southampton is the lead sponsor of 122 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy adults aged 18 to 55 years inclusive on the day of screening
  • Fully conversant in the English language
  • Able to communicate easily by both mobile telephone, email and text messaging
  • Able and willing (in the investigator's opinion) to comply with all study requirements
  • Written to participate in the study
  • Willingness to take a curative antibiotic regimen if / when required according to the study protocol
  • Willingness to abide by infection control guidelines during social contact for the duration of their participation in the study
  • Willingness to attend to the National Institute for Health Research (NIHR) Clinical Research Facility (CRF) Southampton immediately if they become symptomatic
  • Agreement to have no bedroom contacts other than their corresponding contact/challenge volunteer between inoculation and 6 weeks after inoculation
  • Able to answer all questions on the pre-consent questionnaire correctly

Exclusion Criteria:

  • Individuals living in the same households as:

    1. unimmunised or partially immunised children and infants aged \< 1 year
    2. pregnant women >32 weeks who have not received pertussis vaccination at least a week prior to contact
    3. individuals
    4. frail individuals
    5. healthcare workers regularly working with vulnerable individuals as above
  • Individuals who have inviolable commitments within the study period (from day 0 to week 6 + 2 days) to be in close contact with:

    1. unimmunised or partially immunised children and infants aged \< 1 year
    2. pregnant women >32 weeks who have not received pertussis vaccination at least a week prior to contact
    3. immunosuppressed individuals
    4. frail individuals
  • Individuals who live in a boarding school or dormitory during the study.
  • B. pertussis detected on nasal wash taken before the initial challenge
  • Individuals with a confirmed or suspected infection at the time of inoculation with B. pertussis
  • Individuals who have participated in other interventional clinical trials in the last 12 weeks
  • Individuals who have a history of receiving B. pertussis vaccination in the last 5 years
  • Individuals who have previously participated in a B. pertussis human challenge study
  • Individuals who have had a proven B. pertussis infection in the last 5 years
  • Individuals who have a history of never being vaccinated against B. pertussis
  • Current smokers defined as having had a cigarette/cigar in the last week (including vaping)
  • Use of systemic antibiotics within 30 days of or during the challenge
  • Any confirmed or suspected immunosuppressive or immune-deficient state, including infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (topical are allowed)
  • Use of immunoglobulins or blood products within 3 months prior to enrolment
  • History of allergic disease or reactions likely to be exacerbated by any component of the inoculum
  • to the use of azithromycin or macrolides
  • Pregnancy, lactation or intention to become pregnant during the study
  • Any abnormal finding on biochemistry, haematology, toxicology or serological blood tests, urinalysis (see The following reference ranges are provided for the purpose of guidance only. Results that fall outside of these ranges may not be of clinical significance but should be considered on an individual basis.) or clinical examination - in the event of abnormal test results, confirmatory repeat tests will be requested
  • Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data, for example recent surgery to the nasopharynx

Exclusion criteria - Contact volunteers

  • Individuals living in the same households as:

    1. unimmunised or partially immunised children and infants aged \< 1 year
    2. pregnant women
    3. immunosuppressed individuals
    4. frail individuals
    5. healthcare workers working with vulnerable individuals as above
  • Individuals who have inviolable commitments within the study period (from day 0 to week 6 + 2 days) to be in close contact with:

    1. unimmunised or partially immunised children and infants aged \< 1 year
    2. pregnant women >32 weeks who have not received pertussis vaccination at least a week prior to contact
    3. immunosuppressed individuals
    4. frail individuals
  • Individuals who have been involved in other clinical trials involving receipt of an product over the last 12 weeks or if there is planned use of an investigational product during the study period
  • Individuals who have previously participated in a B. pertussis human challenge study
  • Individuals who have a history of never being vaccinated against B. pertussis
  • Any confirmed or suspected immunosuppressive or immune-deficient state, including HIV infection; , asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (topical steroids are allowed)
  • Contraindications to the use of azithromycin or macrolides
  • Any clinically significant abnormal finding on clinical examination
  • Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
  • Pregnancy, lactation or intention to become pregnant during the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Other
    Contact

    Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A 3 day course of Azithromycin will be administered on week 6 if colonised.

    Drug: Azithromycin Pill

  • Experimental
    Challenge

    Challenge volunteers will receive a nasal inoculation containing Bordetella pertussis on Day 0. They will return to the Clinical Research Facility weekly to monitor safety, colonisation and immune responses. A 3 day course of Azithromycin will be administered on week 6 if colonised.

    Biological: Bordetella pertussis B1917 · Drug: Azithromycin Pill

Interventions

  • BiologicalBordetella pertussis B1917

    The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Pertactin (PRN), Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.

  • A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected

06

What researchers measure

Primary outcomes

  1. To assess the incidence of solicited adverse events during prolonged colonisation with Bordetella pertussis following nasal inoculation of healthy adult volunteers

    • Participants will be asked about the occurrence of solicited adverse events at standardised visits. Any symptoms will be recorded and assessed by a study doctor. If deemed necessary by the study doctor further tests will be requested

    Time frame: 6 weeks.

  2. To assess the incidence of unsolicited adverse events during prolonged colonisation with Bordetella pertussis following nasal inoculation of healthy adult volunteers

    Participants will be asked about the occurrence of unsolicited adverse events at standardised visits. Any symptoms will be recorded and assessed by a study doctor. If deemed necessary by the study doctor further tests will be requested

    Time frame: 6 weeks.

  3. To establish the rate of natural clearance of Bordetella pertussis colonisation as detected by nasal wash.

    Bordetella pertussis colonisation will be measured weekly by culture of nasal washes. Putative positive cultures will be confirmed by polymerase chain reaction (PCR).

    Time frame: 6 weeks.

  4. To establish the rate of natural clearance of Bordetella pertussis colonisation as detected by nasopharyngeal swab

    Bordetella pertussis colonisation will be measured weekly by culture of nasopharyngeal swabs. Putative positive cultures will be confirmed by polymerase chain reaction (PCR).

    Time frame: 6 weeks.

Secondary outcomes

  1. To establish the change in colonisation density of Bordetella pertussis during prolonged colonisation as measured from nasal wash samples

    Bordetella pertussis colonisation density will be measured weekly by culture of nasal washes. Putative positive cultures will be confirmed by polymerase chain reaction (PCR).

    Time frame: 6 weeks.

  2. To establish the change in colonisation density of Bordetella pertussis during prolonged colonisation as measured by nasopharyngeal swab samples

    Bordetella pertussis colonisation density will be measured weekly by culture of nasopharyngeal swabs. Putative positive cultures will be confirmed by polymerase chain reaction (PCR).

    Time frame: 6 weeks.

  3. To establish the occurrence of transmission to close contacts during prolonged Bordetella pertussis colonisation

    Bordetella pertussis colonisation density will be measured weekly by culture of nasal washes. Putative positive cultures will be confirmed by polymerase chain reaction (PCR).

    Time frame: 6 weeks.

  4. To establish any association between baseline anti-PT IgG level and protection from colonisation with Bordetella pertussis

    Anti-PT IgG will be measured in blood at baseline (Day 0)

    Time frame: Day 0

  5. To establish any association between baseline anti-PRN IgG level and protection from colonisation with Bordetella pertussis

    Anti-PRN IgG will be measured in blood at baseline (Day 0)

    Time frame: Day 0

  6. To establish any association between baseline anti-FHA IgG level and protection from colonisation with Bordetella pertussis

    Anti-FHA IgG will be measured in blood at baseline (Day 0)

    Time frame: Day 0

  7. To establish any association between baseline anti-FIM IgG level and protection from colonisation with Bordetella pertussis

    Anti-FIM IgG will be measured in blood at baseline (Day 0)

    Time frame: Day 0

  8. To monitor change in anti-PT IgG levels during prolonged colonisation with Bordetella pertussis

    Anti-PT IgG will be measured in blood at standardised timepoints

    Time frame: 6 weeks.

  9. To monitor change in anti-PRN IgG levels during prolonged colonisation with Bordetella pertussis

    Anti-PRN IgG will be measured in blood at standardised timepoints

    Time frame: 6 weeks.

  10. To monitor change in anti-FHA IgG levels during prolonged colonisation with Bordetella pertussis

    Anti-FHA IgG will be measured in blood at standardised timepoints

    Time frame: 6 weeks.

  11. To monitor change in anti-FIM IgG levels during prolonged colonisation with Bordetella pertussis

    Anti-FIM IgG will be measured in blood at standardised timepoints

    Time frame: 6 weeks.

  12. To monitor change in anti-PT IgG levels associated with natural clearance of Bordetella pertussis

    Anti-PT IgG will be measured in blood at standardised timepoints

    Time frame: 6 weeks.

  13. To monitor change in anti-PRN IgG levels associated with natural clearance of Bordetella pertussis

    Anti-PRN IgG will be measured in blood at standardised timepoints

    Time frame: 6 weeks.

  14. To monitor change in anti-FHA IgG levels associated with natural clearance of Bordetella pertussis

    Anti-FHA IgG will be measured in blood at standardised timepoints

    Time frame: 6 weeks.

  15. To monitor change in anti-FIM IgG levels associated with natural clearance of Bordetella pertussis

    Anti-FIM IgG will be measured in blood at standardised timepoints

    Time frame: 6 weeks.

07

Study locations

1 site
  • NIHR Clinical Research Facility
    Southampton, Hampshire SO16 6YD, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2022 to primary completion in Sep 2026, 45 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Dec 2026 → Sep 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
May 6, 2023
StartActual
Dec 6, 2022
Primary completionActual
Sep 29, 2026was Dec 2026
CompletionActual
Sep 29, 2026was Dec 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 6, 2026
Primary completion
Dec 1, 2026→Sep 29, 2026 (actual)
Oct 6, 2026
Study completion
Dec 1, 2026→Sep 29, 2026 (actual)
Oct 6, 2026
Enrollment
72 (estimated)→19 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Completed
    Primary completion Dec 1, 2026→Sep 29, 2026 (now actual)
    Study completion Dec 1, 2026→Sep 29, 2026 (now actual)
    Enrollment 72 (estimated)→19 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05847322
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Dec 6, 2022
Primary completion
Sep 29, 2026
Completion
Sep 29, 2026
Last update
Oct 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion